Navigation Links
SemBioSys announces 2007 third quarter results
Date:11/1/2007

Sys is developing a series of non-pharmaceutical products addressing human topical, nutritional oils and animal health markets.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions and market size, the acceptance of an IND by the FDA in respect of clinical studies and the successful and timely completion of clinical studies, the fact that Apo AI is currently a development stage drug, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at http://www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

Financials results included below:

SemBioSys Genetics Inc.

Consolidated Balance Sheets

(Unaudited)

As at September 30, 2007 and December 31, 2006

----------------------------------
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ) ("NW ... for cancer, announced today that Dr. Marnix L. ... be making an Industry Expert Theater Presentation at the ... on Saturday, May 30, 2015, from 3 to ... McCormick Place. Dr. Bosch will provide an ...
(Date:5/27/2015)... , May 27, 2015  RXi Pharmaceuticals Corporation ... on discovering and developing innovative therapies primarily in ... update on the status of the Company,s Series ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... and 21 shares of Series A Preferred Stock ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Regenestem ... new stem cells clinic in Buenos Aires, Argentina. The ... renowned critical care specialist. Pastrana has assembled a multidisciplinary ... and orthopedics in her state-of-the-art Puerto Madero office. ... phase I to phase IV clinical studies in cellular ...
(Date:5/26/2015)... REDWOOD CITY, California and HILDEN, ... -- QIAGEN N.V. (NASDAQ: QGEN ... commercial launch of its QIAGEN Clinical Insight ® ... clinical testing labs to interpret and report on ... first two supported applications for the bioinformatics platform ...
Breaking Biology Technology:NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 2QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 4QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 5
... with modest growth in the,traditional life science ... in agricultural, biodefense and molecular diagnostics. To,help ... and,advisory firm BioInformatics, LLC today released its ... of scientists working in,these dynamic markets. The ...
... million in ... 2007-, - sNDA submitted for ... showing favorable results - - New proteasome inhibitor, MLN2238, enters development ... 2007 net income financial guidance -, CAMBRIDGE, Mass., Jan. 4 Building ...
... QuatRx clinical development programs, including review of positive results from ... ... ARBOR, Mich., Jan. 4 QuatRx Pharmaceuticals Company,today announced that the ... at the 26th Annual JP Morgan Healthcare,Conference on Tuesday, January 8th, ...
Cached Biology Technology:Study Examines Media Preferences of Life Scientists in Applied Markets 2Study Examines Media Preferences of Life Scientists in Applied Markets 3Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results 2Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results 3Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results 4Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results 5Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results 6Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results 7Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results 8Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results 9QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference 2
(Date:5/22/2015)... CT , May 22, 2015  NXT-ID, Inc. (NASDAQ: ... June 1st, it will be ending its promotional pricing and ... . Laurence Savin , Head of Marketing ... exclusive promotional pricing until the end of May. To get ... wocketwallet.com/invite and when we open the store on June 1, ...
(Date:5/21/2015)... May 21, 2015 The Sync Project™ ... music for health, today announced a collaborative partnership with ... partnership will center on collaboration on original research, joint ... step in the collaboration, The Sync Project and BerkleeICE ... as Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... of corn for ethanol production occur, the harm to ... at the regional and local levels could also arise, ... The committee that wrote the report examined policy ... technologies to help minimize effects of biofuel production on ...
... how thousands of chemicals found in the environment may ... cause disease is becoming easier because of a new ... issued today by the National Academies of Sciences (NAS) ... human health and recommends the integration of toxicogenomics into ...
... 10, 2007) -- A few came. They ran. They left. ... Corp begins training in 2008 in new running suits chosen ... environmental chamber. The experience was enough to make both ... researchers were unaware that it was InSport,s training clothes that ...
Cached Biology News:Increase in ethanol production from corn could significantly impact 2Increase in ethanol production from corn could significantly impact 3NAS report offers new tools to assess health risks from chemicals 2Marines land at UO, leave with plans to wear Oregon-made training suits 2Marines land at UO, leave with plans to wear Oregon-made training suits 3
... A-20 cells were cultured in RPMI 1640 with ... phase of growth. In order to keep ... fixed in acetone-methanol. The cells are arrayed ... with each wells surface specifically treated to enhance ...
... are derived from the Spodoptera frugiperda Sf21 cell ... in transfections, plaque assays, virus production, and protein ... that optimizes recovery of viable cells after thawing. ... Insect Cell Medium and can also be grown ...
... CrysScreen is a software package ... user interface for custom buffer creation, ... management in crystallization trials. The software ... steps in automated protein crystallography: ...
... Polymerase is a premium quality recombinant form ... enzyme is suitable for a wide range ... purity and reproducible performance, each preparation is ... control assays. NovaTaq DNA Polymerase possesses an ...
Biology Products: